Anne Brindley
Plus aucun poste en cours
Profil
Anne Brindley served as Chief Executive Officer at Advent Pharmaceuticals Pty Ltd., Nuformix Plc, and Auroscience (Pty) Ltd.
She also worked as Director-Product Development at AstraZeneca PLC and as Managing Director & Vice President at RespiVert Ltd.
from 2013 to 2017.
Prior to these roles, she was Executive VP-Pharmaceutical Development at SkyePharma Plc.
Dr. Brindley started her career as a Senior Scientist at GSK Plc from 1992 to 1995.
She earned an undergraduate degree from the University of Bath and a doctorate from The University of Nottingham.
Anciens postes connus de Anne Brindley
| Sociétés | Poste | Fin |
|---|---|---|
| Auroscience (Pty) Ltd. | Directeur Général | 01/02/2020 |
RespiVert Ltd.
 RespiVert Ltd. Medical DistributorsDistribution Services RespiVert Ltd. operates as a small molecule drug discovery company. The firm develops small-molecule inhaled therapies for the treatment of chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. The company was founded by William Garth Rapeport, Peter Strong, Kazuhiro Ito, John Murray and Peter Barnes in 2007 and is headquartered in London, the United Kingdom. | Directeur Général | 28/02/2017 |
| GSK PLC | Directeur Technique/Scientifique/R&D | 01/12/1995 |
Advent Pharmaceuticals Pty Ltd.
 Advent Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology Advent Pharmaceuticals Pty Ltd. designs and develops dry powder inhaler devices. The firm focuses on the development of dry powder inhalation platforms for the treatment of asthma and chronic obstructive pulmonary diseases. The company was founded by Henry Kenneth Windle in 2001 and is headquartered in Melbourne, Australia. | Directeur Général | - |
| NUFORMIX PLC | Directeur Général | - |
Formation de Anne Brindley
| University of Bath | Undergraduate Degree |
| The University of Nottingham | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| GSK PLC | Health Technology |
| NUFORMIX PLC | Health Technology |
| Entreprise privées | 4 |
|---|---|
SkyePharma Plc
 SkyePharma Plc Pharmaceuticals: OtherHealth Technology SkyePharma Plc engaged in the provision of pharmaceutical business. It involved in development and supply of pharmaceutical products. The company was founded by Ian Roderick Gowrie-Smith on August 18, 1910 and was headquartered in London, the United Kingdom. | Health Technology |
RespiVert Ltd.
RespiVert Ltd. Medical DistributorsDistribution Services RespiVert Ltd. operates as a small molecule drug discovery company. The firm develops small-molecule inhaled therapies for the treatment of chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. The company was founded by William Garth Rapeport, Peter Strong, Kazuhiro Ito, John Murray and Peter Barnes in 2007 and is headquartered in London, the United Kingdom. | Distribution Services |
Advent Pharmaceuticals Pty Ltd.
Advent Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology Advent Pharmaceuticals Pty Ltd. designs and develops dry powder inhaler devices. The firm focuses on the development of dry powder inhalation platforms for the treatment of asthma and chronic obstructive pulmonary diseases. The company was founded by Henry Kenneth Windle in 2001 and is headquartered in Melbourne, Australia. | Health Technology |
| Auroscience (Pty) Ltd. |
